Little is known about patients prescribed high doses of opioids to treat chronic non-cancer pain, though these patients may be at higher risk for medication-related complications. We describe the prevalence of high-dose opioid use and associated demographic and clinical characteristics among veterans treated in a VA regional healthcare network. Veterans with chronic non-cancer pain prescribed high doses of opioids (P 180 mg/day morphine equivalent; n = 478) for 90+ consecutive days were compared to two groups with chronic pain: Traditional-dose (5-179 mg/day; n = 500) or no opioid (n = 500). High-dose opioid use occurred in 2.4% of all chronic pain patients and in 8.2% of all chronic pain patients prescribed opioids long-term. The average dose in the high-dose group was 324.9 (SD = 285.1) mg/day. The only significant demographic difference among groups was race (p = 0.03) with black veterans less likely to receive high doses. High-dose patients were more likely to have four or more pain diagnoses and the highest rates of medical, psychiatric, and substance use disorders. After controlling for demographic factors and VA facility, neuropathy, low back pain, and nicotine dependence diagnoses were associated with increased likelihood of high-dose prescriptions. High-dose patients frequently did not receive care consistent with treatment guidelines: there was frequent use of short-acting opioids, urine drug screens were administered to only 25.7% of patients in the prior year, and 32.0% received concurrent benzodiazepine prescriptions, which may increase risk for overdose and death. Further study is needed to identify better predictors of high-dose usage, as well as the efficacy and safety of such dosing.
Introduction
The use of opioids for chronic non-cancer pain has increased in recent years [10, 31] despite uncertainty regarding the efficacy of opioids in reducing pain or improving function [24, 32] . A summary of the literature regarding opioid medications to treat chronic noncancer pain indicates strong evidence of initial effectiveness in pain reduction, but less evidence to support long-term effectiveness [6, 13] .
Doses of opioid medications often remain stable [47] and the vast majority of pain patients are on opioid doses less than 100 mg morphine equivalents per day [40] . However, a small proportion of patients are prescribed high doses (defined here as greater than 180 mg morphine equivalent per day [5] ). Limited empirical data are available regarding the prevalence of high-dose opioid use, clinical or demographic factors associated with highdose opioid use, or outcomes associated with long-term high-dose opioid therapy [12] . Of the few randomized clinical trials that included high doses of opioids, time on active treatment was limited to one to eight weeks [5] . A planned three year registry study of patients taking controlled-release oxycodone for non-cancer pain found that, of 233 patients enrolled, 5% were taking 100 mg or more of oxycodone per day [40] . However, treatment discontinuation was high, as 133 (57%) participants voluntarily terminated the study, and the data on long-term benefit are not available. In a study of 1226 patients with disabling musculoskeletal disorders, higher baseline opioid doses (greater than 61 mg morphine equivalent per day) were associated with poorer outcomes from an interdisciplinary functional restoration program [28] .
There are numerous risks associated with opioids, including side effects, misuse, diversion, and other adverse health effects [27, 34, 35, 44] , in addition to concerns about effectiveness. These concerns are heightened for patients on high doses of opioids. There may also be additional side effects associated with highdose opioid use that are not present at standard dose, such as
